PDL BioPharma, Inc. (NASDAQ:PDLI) Broker Price Targets For The Coming Week

Josh Kim
January 1, 2017

The company reported $0.08 earnings per share for the quarter, meeting analysts' consensus estimates of $0.08. Organovo Holdings, Inc. has P/S value of 115.44 while its P/B value stands at 6.41. The company shows Gross Margin and Operating Margin of 82.2 percent and 0 percent respectively.

Insider Trades for PDL BioPharma, Inc. show that the latest trade was made on 8 Aug 2016 where Garcia (Peter S), the Chief Financial Officer completed a transaction type "Buy" in which 5000 shares were traded at a price of $2.99. The volume of the company in the last trading session was 1.44 Million. (NASDAQ:PDLI). According to First Call, the consensus price target for the company is $3.67.

The Stock now has Analyst' mean Recommendation of 1.5 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell. Similarly, the company has Return on Assets of -57.3 percent, Return on Equity of -62.1 percent and Return on Investment of -62.1 Percent.

Organovo Holdings, Inc.is estimated to report earnings on 02/13/2017. While in the same Quarter Previous year, the Actual EPS was $0.62.

PDL BioPharma, Inc. (NASDAQ:PDLI) has the market capitalization of $352.29 Million.

PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. This estimate is provided by 2 analysts.

Camila Cabello Leaving Fifth Harmony (Statement)
The statement says, "We are four strong, committed women who will continue with Fifth Harmony as well as our solo endeavors". Fifth Harmony have announced that Camila Cabello has left the group.

According to 2 analysts, the Average Revenue Estimate for the current Fiscal quarter is $56.37 Million and the Low Revenue estimate is $46.6 Million, while the High Revenue estimate is $66.13 Million.

Our vendor, Zacks Investment Research, hasn't provided us with the upcoming earnings report date. The most recent bid on the stock was registered at $2.12. Analysts rating the company a 3 indicate a Hold recommendation.

Shares of PDLI have been given average recommendation of "Overweight" rating keeping in view the consensus of "3" Analysts. The 52-Week High range of the stock is $3.84, while the 52-week low range is $1.93. Narrowing in further, the stock has been recently noted at -43.77% away from the 50 day high and 9.84% separated from the 50 day low. The company has volume of 1.49 Million shares. EPS Estimate for Next Fiscal Year is stands at $0.19. The company reported Earnings of $0.08 in last Quarter's while the company declared Earnings of $1.94 in past year. This shows a surprise factor of 0 percent.

The Company now has ROA (Return on Assets) of 16.1 percent, Return on Equity (ROE) of 23.9 Percent and Return on Investment (ROI) of 37.8% with Gross margin of 0 percent and Operating & Profit margin of 85.7% and 49% respectively.

The stock is now showing YTD performance of -37.38 Percent. Analysts rating the company a 4 or 5 indicate a Sell recommendation.

Other reports by MyHealthBowl

Discuss This Article